(RTTNews) - Ultragenyx Pharmaceutical Inc. (RARE) announced on Wednesday that it has agreed to sell a Rare Pediatric Disease Priority Review Voucher for $203 million.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。
Veytics Intelligence
Ultragenyx To Sell Rare Pediatric Disease Priority Review Voucher For $203 Mln
